Furthermore, a secondary endpoint of both NEJ 002 [33] and WJTOG3405 [34] prospectively showed identical OS between gefitinib and chemotherapy in first-line treatment of NSCLC patients harboring sensitive EGFR mutations (Table 2), although OS data from OPTIMAL and EURTAC are immature at the present time. Here, EGFR is linked to non-small cell lung carcinoma.